Press release
Investors who lost money with shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) should contact the Shareholders Foundation
A lawsuit was filed on behalf of investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares.
If you purchased a significant amount of shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, and / or if you purchased any NASDAQ: VTGN shares prior to April 2024 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: March 16, 2026. NASDAQ: VTGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
San Francisco, CA based Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
On December 17, 2025, Vistagen Therapeutics, Inc. revealed that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on the primary endpoint of change on the Subjective Units of Distress Scale. In pertinent part, defendants allegedly announced the trial did not achieve its primary endpoint and there was no treatment difference between fasedienol and placebo for the secondary endpoints.
Shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) declined from $5.74 per share on April 04, 2024, to as low as #0.62 per share on January 21, 2025.
According to the complaint the plaintiff alleges on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common shares between April 1, 2024 and December 16, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 1, 2024 and December 16, 2025, the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that fasedienol's positive results achieved in the previous PALISADE-2 trial, in addition to notable enhancements and operational changes made to the execution of the PALISADE-3 clinical trial, supported a strong likelihood of Phase 3 success and positioned it as a confirmatory study, and that in reality, the complaint alleges, defendants had knowingly or recklessly omitted the risk of failure inherent in public speaking challenge-based social anxiety disorder clinical trials.
Those who purchased shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) have certain options and should contact the Shareholders Foundation
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
Web: www.shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investors who lost money with shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) should contact the Shareholders Foundation here
News-ID: 4387049 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation Alert: Investors who hold shares of Inovio Pharmaceuticals, Inc. ( …
An investigation was announced for current long-term investors in shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) concerning potential breaches of fiduciary duties by certain directors of Inovio Pharmaceuticals, Inc.
Investors who are current long term investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Power Solutions International, Inc. (NASDAQ: PSIX) Investor Alert: Deadline in L …
A deadline is coming up on May 19, 2026 in the lawsuit filed for certain investors of Power Solutions International, Inc. (NASDAQ: PSIX) over alleged securities laws violations by Power Solutions International, Inc.
Investors who purchased shares of Power Solutions International, Inc. (NASDAQ: PSIX) have certain options and there are strict and short deadlines running. Deadline: May 19, 2026. Power Solutions International, Inc. (NASDAQ: PSIX) stockholders should contact the Shareholders…
Long-Term Investors who hold shares of Kyndryl Holdings, Inc. (NYSE: KD) should …
An investigation was announced on behalf of current long-term investors in shares of Kyndryl Holdings, Inc. (NYSE: KD) concerning potential breaches of fiduciary duties by certain directors and officers of Kyndryl Holdings, Inc.
Investors who are current long term investors in Kyndryl Holdings, Inc. (NYSE: KD) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
Lawsuit Alert: Investors who lost money with shares of Immutep Limited (NASDAQ: …
An investor, who purchased shares of Immutep Limited (NASDAQ: IMMP), filed a lawsuit over alleged violations of Federal Securities Laws by Immutep Limited in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Immutep Limited (NASDAQ: IMMP) have certain options and for certain investors are short and strict deadlines running. Deadline: July 6, 2026. NASDAQ: IMMP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
More Releases for Vistagen
Ketamine treatment Market Set to Witness Significant Growth by 2033 | Upsher-Smi …
In 2024, the market was valued at approximately USD 0.50 billion. By 2033, it is projected to reach around USD 6.08 billion, reflecting a compound annual growth rate (CAGR) of 31.52% from 2025 to 2033.
Ketamine treatment Market Overview
The global ketamine treatment market is experiencing rapid growth, driven by increasing recognition of ketamine's efficacy in treating mental health disorders, particularly treatment-resistant depression. This expansion is fueled by advancements in ketamine-based…
Social Anxiety Disorder Market to Witness Rise During the Forecast Period | Bion …
According to DelveInsight, the market for Social Anxiety Disorder is expected to experience significant growth in the near future, driven by heightened research and development efforts, a growing number of affected individuals, and the anticipated success of new treatments in the seven major markets. Key players like Vistagen Therapeutics with PH94B, Vanda Pharmaceuticals with VQW-765, and Bionomics with BNC210, among others, are actively engaged in advancing the Social Anxiety Disorder…
Ph94b by VistaGen Therapeutics expected to drive market size of Generalized Anxi …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Ph94b (VistaGen Therapeutics) providing insights into the drug market landscape and market forecast of Ph94b upto 2032. The report, titled "PH94B Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of Ph94b in 2032? Ph94b Market…
Synthetic Stem Cells Market Next Big Thing| Major Giants Gamida Cell, Pluristem …
Advance Market Analytics published a new research publication on "Synthetic Stem Cells Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Synthetic Stem Cells market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample…
Vistagen Therapeutics, Inc. "AV-101 market size expected to increase many folds …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on AV-101 (Vistagen Therapeutics, Inc.) providing insights into the drug market landscape and market forecast of AV-101 upto 2032. The report, titled "AV-101 Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of AV-101 in 2032? AV-101…
Factors Influencing Global Depression Treatment Therapy Market through 2022 and …
Stratagem Market Insights published a report titled "Depression Treatment Therapy Market" research report which covers comprehensive data on prevalent trends, drivers, growth opportunities, and restraints that can change the market dynamics of the global industry. This report provides an in-depth analysis of the market segmentation that includes products, applications, and geographical analysis. Global Depression Treatment Therapy market report delivers a close watch on leading competitors with strategic analysis, micro and…
